“…To date, most studies addressing the effect of HAART on HCMV-specific immunity have been conducted in HIV patients in late stage disease either at high risk of developing HCMV or already presenting the latter. In these patients, control of HCMV replication, which rapidly follows response to HAART [Deayton et al, 1999], has been linked to recovery of lymphoproliferative response (LPR) to HCMV [Li et al, 1998;Gerna et al, 2001;Hsieh et al, 2001;Jacobson et al, 2001]; however, a number of studies have provided data showing that a lack of progression to HCMV disease is not always associated with the presence of robust LPRs to HCMV [Villacres et al, 2001;Weinberg et al, 2001;Berenguer et al, 2002;Tamarit et al, 2004]-thus seriously questioning the value of the LPRs to HCMV as a surrogate marker for protection against HCMV disease. Likewise, when evaluation of CD4 þ T cell immunity against HCMV in these patients has been assessed by flow cytometric detection of intracellular cytokines following short-term antigenic stimulation of PBMCs, an invariable association between the presence of HCMV disease and negative cytokine responses has not been proven [Jacobson et al, 2001].…”